PolyPid Ltd.: Rosalind Advisors, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Rosalind Advisors, Inc. amended its Schedule 13G beneficial ownership filing for PolyPid Ltd., per SEC accession 0001622627-26-000030. The filing updates the advisor's reported stake in the Israeli drug developer, though the amended document did not disclose a revised share count or percentage in the headline details. Schedule 13G amendments are typically filed when a passive investor's position crosses or moves past the 5% threshold or when previously reported holdings change materially. Investors will watch for the specific share total and ownership percentage in the full filing to gauge whether Rosalind increased or trimmed its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Rosalind Advisors, Inc., PolyPid Ltd.